Faculty profile

Sita Bhella

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Toronto

Sita Bhella

Assistant Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
12 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

218

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy
Transplantation and Cellular Therapy · 2026 · senior author
GVHD Prophylaxis With ATG and PTCy Versus PTCy-Based Regimens in Haploidentical Stem Cell Transplantation: A CTTC Study.
Transplantation and cellular therapy · 2026
Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.
Blood advances · 2026

All 14 publications

14 publications.

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

Buchan CA, Agbayani G, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G

Transplantation and Cellular Therapy20263 citationsSenior author

DOI: 10.1016/j.jtct.2025.10.037

GVHD Prophylaxis With ATG and PTCy Versus PTCy-Based Regimens in Haploidentical Stem Cell Transplantation: A CTTC Study.

Garcia-Horton A, Salter B, Paulson K, Musto G, Ikuomola O, Bucher O, Seftel M, Truong TH, Hay KA, Prica A, Bhella S, Mattsson J, Pasic I

Transplantation and cellular therapy20261 citations

DOI: 10.1016/j.jtct.2026.03.025 PMID: 41871755

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Kordbacheh T, Chan KKW, Crump M, Ante Z, Liu N, Aminilari M, Gong IY, Bhella S, Vijenthira A, Kuruvilla J, Kridel R, Chen C, Kukreti V, Yang C, Hodgson D, Prica A, Rodin D

Blood advances20261 citationsOpen Access

DOI: 10.1182/bloodadvances.2025017401 PMID: 41544221

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM

Blood advances2026First authorOpen Access

DOI: 10.1182/bloodadvances.2025018117

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Gong IY, Xiao NM, Chen C, Bhella S, Hueniken K, Marinoni M, Azab M, Aoki T, Kridel R, Kukreti V, Vijenthira A, Yang C, Rodin D, Jeeva M, Aminilari M, Malik N, Wells W, Hodgson D, Crump M, Prica A, Kuruvilla J

Leukemia & lymphoma2026

DOI: 10.1080/10428194.2026.2682290 PMID: 42295978

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Gong IY, Jeeva M, Hueniken K, Aminilari M, Marinoni M, Prica A, Rodin D, Bhella S, Aoki T, Azab M, Chen C, Kridel R, Kukreti V, Vijenthira A, Yang C, Malik N, Wells W, Metser U, Crump M, Hodgson D, Kuruvilla J

Hematological oncology2026

DOI: 10.1002/hon.70183 PMID: 41774783

Outcomes of Primary Mediastinal B-cell Lymphoma Patients with Partial Metabolic Response: A Multicenter Retrospective Analysis.

Wattakiyanon N, Aminilari M, Ye XY, Metser U, Prica A, Crump M, Kuruvilla J, Kukreti V, Kridel R, Vijenthira A, Bhella S, Cheung M, Vivekanandan T, Rodin D, Tsao M, Hodgson D

Advances in radiation oncology20251 citationsOpen Access

DOI: 10.1016/j.adro.2025.101744 PMID: 40291511

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

Vijenthira A, Bhella S, Hueniken K, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Balitsky A

British Journal of Haematology2025Open Access

DOI: 10.1111/bjh.70054

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G

Vaccine20247 citationsFirst authorOpen Access

DOI: 10.1016/j.vaccine.2024.06.041

Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study

Matthew D. Seftel, Ivan Pašić, Gaganvir Parmar, Oliver Bucher, David Allan, Sita Bhella, Kevin Anthony Hay, Oluwaseun Ikuomola, Grace Musto, Anca A. Prica, Erin Richardson, Tony H. Truong, Kristjan Paulson

Current Oncology20238 citationsOpen Access

DOI: 10.3390/curroncol30110723 PMID: 37999143

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Sita Bhella

Research

Latest papers

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

GVHD Prophylaxis With ATG and PTCy Versus PTCy-Based Regimens in Haploidentical Stem Cell Transplantation: A CTTC Study.

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Outcomes of Primary Mediastinal B-cell Lymphoma Patients with Partial Metabolic Response: A Multicenter Retrospective Analysis.

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study

Frequent collaborators

Anca Prica

Abi Vijenthira

John Kuruvilla

Robert Kridel

Vishal Kukreti

Michael Crump

David Hodgson

Amaris Karin Balitsky

Curtis Cooper

Annette Hay

Danielle Rodin

Marc-André Langlois

Michael Sebag

Ivan Pasic

Christine Chen

Chloe Yang

Inna Gong

Lisa Hicks

David Allan

Woodrow Wells

Nauman Malik

Matthew Cheung

Christopher Bredeson

Angela Crawley

Tony Reiman

Jonas Mattsson

Natasha Kekre

Tony Truong

Kristjan Paulson

Farheen Manji

May Tsao

Vikas Gupta

Auro Viswabandya

Ur Metser

Wilson Lam